Child | Age
Item
a male or female child 12 or 13 months of age at the time of entry into the enrollment phase,
boolean
C0008059 (UMLS CUI [1])
C0001779 (UMLS CUI [2])
Health Complaints Free of
Item
free of obvious health problems,
boolean
C0871764 (UMLS CUI [1,1])
C0332296 (UMLS CUI [1,2])
Prevnar Dosage Quantity | Life year First
Item
subjects must have previously received three doses of prevnar in his/her first year of life.
boolean
C0876134 (UMLS CUI [1,1])
C0178602 (UMLS CUI [1,2])
C1265611 (UMLS CUI [1,3])
C0376558 (UMLS CUI [2,1])
C0439234 (UMLS CUI [2,2])
C0205435 (UMLS CUI [2,3])
Investigational New Drug | Drug, Non-Prescription | Vaccine
Item
use of any investigational or non-registered drug or vaccine within 42 days preceding the first dose of study vaccine, or planned use during the study period,
boolean
C0013230 (UMLS CUI [1])
C0013231 (UMLS CUI [2])
C0042210 (UMLS CUI [3])
Immunosuppressive Agents chronic | Biological Response Modifiers chronic | Adrenal Cortex Hormones | Prednisone | Prednisone Equivalent | inhaled steroids | Steroids Nasal | topical steroids
Item
chronic administration of immuno-suppressant or other immune-modifying drugs within six months prior to vaccination or planned administration at any time during the study period. (for corticosteroids, this will mean prednisone, or equivalent, less than 0.5 mg/kg/day. inhaled, nasal and topical steroids are allowed.),
boolean
C0021081 (UMLS CUI [1,1])
C0205191 (UMLS CUI [1,2])
C0005525 (UMLS CUI [2,1])
C0205191 (UMLS CUI [2,2])
C0001617 (UMLS CUI [3])
C0032952 (UMLS CUI [4])
C0032952 (UMLS CUI [5,1])
C0205163 (UMLS CUI [5,2])
C2065041 (UMLS CUI [6])
C0038317 (UMLS CUI [7,1])
C1522019 (UMLS CUI [7,2])
C2064827 (UMLS CUI [8])
Prevnar Dosage Fourth
Item
administration of the acip-recommended fourth dose of prevnar prior to entering the enrollment phase of the study,
boolean
C0876134 (UMLS CUI [1,1])
C0178602 (UMLS CUI [1,2])
C0205438 (UMLS CUI [1,3])
Administration of vaccine Study Protocol
Item
planned administration or administration of any vaccine not foreseen by the study protocol within the period of 42 days before and 30 days after each dose of study vaccine(s),
boolean
C2368628 (UMLS CUI [1,1])
C2348563 (UMLS CUI [1,2])
Hepatitis A immunization
Item
previous vaccination against hepatitis a,
boolean
C0419735 (UMLS CUI [1])
Hepatitis A | Hepatitis A Exposure to
Item
history of hepatitis a or known exposure to hepatitis a,
boolean
C0019159 (UMLS CUI [1])
C0019159 (UMLS CUI [2,1])
C0332157 (UMLS CUI [2,2])
Immunosuppression | Immunologic Deficiency Syndromes | HIV Infections
Item
any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (hiv) infection,
boolean
C4048329 (UMLS CUI [1])
C0021051 (UMLS CUI [2])
C0019693 (UMLS CUI [3])
Immunodeficiency congenital Family history | Immunologic Deficiency Syndromes Hereditary Family history | HIV Infections Family history | parent risk factors HIV Infections
Item
a family history of congenital, hereditary or infectious immunodeficiency or parental risk factors for hiv infection,
boolean
C0853602 (UMLS CUI [1,1])
C0241889 (UMLS CUI [1,2])
C0021051 (UMLS CUI [2,1])
C0439660 (UMLS CUI [2,2])
C0241889 (UMLS CUI [2,3])
C0019693 (UMLS CUI [3,1])
C0241889 (UMLS CUI [3,2])
C0030551 (UMLS CUI [4,1])
C0035648 (UMLS CUI [4,2])
C0019693 (UMLS CUI [4,3])
Hypersensitivity Exacerbated Due to Havrix Component | Allergic Reaction Exacerbated Due to Havrix Component | Neomycin | Phenoxyethanol | Prevnar | diphtheria toxoid
Item
history of allergic disease/reactions or hypersensitivity likely to be exacerbated by any component of havrix (e.g., neomycin, 2-phenoxyethanol) or prevnar (e.g., diphtheria toxoid),
boolean
C0020517 (UMLS CUI [1,1])
C1444749 (UMLS CUI [1,2])
C0678226 (UMLS CUI [1,3])
C0700881 (UMLS CUI [1,4])
C1705248 (UMLS CUI [1,5])
C1527304 (UMLS CUI [2,1])
C1444749 (UMLS CUI [2,2])
C0678226 (UMLS CUI [2,3])
C0700881 (UMLS CUI [2,4])
C1705248 (UMLS CUI [2,5])
C0027603 (UMLS CUI [3])
C0301042 (UMLS CUI [4])
C0876134 (UMLS CUI [5])
C0012551 (UMLS CUI [6])
Congenital defects Major | Chronic disease Serious
Item
major congenital defects or serious chronic illness,
boolean
C0220810 (UMLS CUI [1,1])
C0205164 (UMLS CUI [1,2])
C0008679 (UMLS CUI [2,1])
C0205404 (UMLS CUI [2,2])
nervous system disorder | Febrile Convulsions
Item
history of any neurologic disorder (history of febrile seizures not associated with an underlying neurological disorder does not exclude the subject),
boolean
C0027765 (UMLS CUI [1])
C0009952 (UMLS CUI [2])
Disease | Illness Moderate | Illness Severe | Illness Moderate Associated with Fever | Illness Severe Associated with Fever
Item
acute disease, defined as the presence of a moderate or severe illness with or without fever, at the time of vaccination,
boolean
C0012634 (UMLS CUI [1])
C0221423 (UMLS CUI [2,1])
C0205081 (UMLS CUI [2,2])
C0221423 (UMLS CUI [3,1])
C0205082 (UMLS CUI [3,2])
C0221423 (UMLS CUI [4,1])
C0205081 (UMLS CUI [4,2])
C0332281 (UMLS CUI [4,3])
C0015967 (UMLS CUI [4,4])
C0221423 (UMLS CUI [5,1])
C0205082 (UMLS CUI [5,2])
C0332281 (UMLS CUI [5,3])
C0015967 (UMLS CUI [5,4])
Immunoglobulins | Blood product
Item
administration of immunoglobulins and/or any blood products within three months prior to the first dose of study vaccine or planned administration at any time during the entire study period.
boolean
C0021027 (UMLS CUI [1])
C0456388 (UMLS CUI [2])